curve guardian glp-1 trends 2025: real-world data, patient outcomes & future therapies GLP1 Research Products: Novus Biologicals
Description
Understanding these changes helps you track treatment progress and identify any need for dose adjustments
Without intentional protein intake, some individuals may struggle to preserve lean muscle mass during weight loss
Our pilot data suggest no additional improvement in glycaemic control or BW with LAGB and liraglutide therapy
DNF-10 yeast peptides have been shown to help reduce cravings and quiet the food talk
Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada
These findings align with prior randomized trials and meta-analyses suggesting class-level cardiovascular benefit
